ADC Process Development Summit on October 22-23, 2025 in Boston, United States

Underpinning successful ADC development is a robust, reproducible, and scalable process development strategy. From controlling impurities and optimizing conjugation yield to streamlining unit operations and executing technology transfer, it’s clear that the path to successful commercialization is enabled by a strong process development strategy.

Returning to Boston this October, the 3rd ADC Process Development Summit is the only meeting dedicated to the technical and strategic challenges of ADC process development. In an intimate setting, join 80+ experts from AstraZeneca, Merck, Gilead, Genentech, AbbVie, and more for two days of focused insights, real-world case studies, and peer-led discussion to revolutionize your antibody-drug conjugate manufacturing process..

Don’t miss this chance to uncover how to streamline purification strategies, scale up emerging conjugation approaches, define CQA-driven specifications, and scale up manufacturing while meeting evolving regulatory expectations. Whether you’re supporting early-stage development or preparing for pivotal trials and BLA submissions, this is your opportunity to benchmark, troubleshoot, and advance your ADC process with confidence.

URLs:

Tickets: https://go.evvnt.com/3156903-1?pid=10008

Brochure: https://go.evvnt.com/3156903-2?pid=10008

Time: 9:00 AM - 5:00 PM

Prices:

Drug Developer - Conference Only: USD 2999.00,

Academic - Conference Only: USD 2599.00,

Solution Providers - Conference Only: USD 3699.00

Speakers: Christopher Spedaliere, Senior Scientist Regulatory CMC, Merck and Co., Esohe Idusogie, Vice President - Global Quality Control and Analytical Chemistry, ADC Therapeutics, Eunju Jang, Senior Scientist, AbbVie, Hiroki Tanemura, Upstream Cell Culture Process Development Professional, Daiichi Sankyo, Jiten Patel, Principal Scientist, Johnson and Johnson, John Kavouris, Scientist II, Process Development, AbbVie, Juan Cordova, Associate Director, CMC, Eli Lilly, Karthik Narsimhan, Senior Development Engineer, AbbVie, Laurencia Zongo, Scientist, Purification Process Sciences, AstraZeneca, Neha Kothari, Principal Scientist, Johnson and Johnson, Sunny Zhang, Senior Director Pharmaceutical Development, ADC Therapeutics, Sunny Zhou, Professor, Northeastern University, Wei Lin, Associate Principal Scientist, Merck and Co., Weijun Li, Senior Director, Biologics Analytical / CMC Lead, Exelixis, Yun Bai, Executive Vice President, CMC, Santa Ana Bio